Figure 5.

Combination of tasquinimod with Anti-PD-L1 therapy synergistically reduces tumor growth. (A) Study design: Subcutaneous MBT-2 tumors were allowed to grow until reaching an average size ranging between 50 and 100 mm³ (day 8). Mice (n = 16) were treated with IgG2B (control), Anti-PD-L1, tasquinimod or the combination of tasquinimod + Anti-PD-L1. (B) Tumor growth curves represent serial caliper measurements. Error bars indicate mean ± SEM (One-way ANOVA; **p < 0.005, ***p < 0.001). Tumor weights at the endpoint (day 15) are shown in (C) (Kruskal–Wallis test; *p < 0.05, **p < 0.005, ***p < 0.001). The experiments were repeated at least four times. Results from one representative experiment are shown.